Conferences

CROI 2024

The 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) was held in Denver, US, from 3 to 6 March.
CROI 2024
Sexually transmitted infections prevention

Sexually transmitted infections in San Francisco have fallen since doxyPEP roll-out

New & experimental HIV treatments

Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment

The search for a cure

Drugs that make HIV-infected cells self-destruct induce profound viral load drops in mice after just one or two doses

Health problems in children & young people

Young adults with HIV have high prevalence of heart disease risk factors

Injectable & long-acting PrEP

Why is the roll-out of injectable PrEP taking so long?

Weight gain & lipodystrophy

Weight gain on HIV treatment: more than a 'return to health' phenomenon?

Ageing & HIV

The US opioid crisis has reached older people with HIV

HIV treatment for children & young people

Adolescents prefer long-acting injectables to daily oral HIV treatment, study finds

Epidemiology

Almost two-thirds of new HIV cases occur outside southern and eastern Africa

Epidemiology

Top 5 stories on HIV in the US from CROI 2024

PrEP programmes & uptake

People who inject drugs in the US are more aware of PrEP, but aren’t taking it

Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and PrEP from CROI 2024

Harm reduction

Over 30 years, big fall in HIV among people who inject drugs in Baltimore, but hepatitis C remains high

Women

Top 5 stories on HIV and women from CROI 2024

PrEP

Top 5 HIV PrEP stories from CROI 2024

Injectable & long-acting HIV treatment

Long-acting injectables can be a good option for people with adherence challenges

Health problems & ageing

Top 5 stories on co-morbidities affecting people with HIV from CROI 2024

PrEP policies & guidelines

Should event-driven PrEP be an option for women?

Low CD4 count

Nearly two million people in sub-Saharan Africa may have advanced HIV disease

HIV treatment

Top 5 HIV treatment stories from CROI 2024

Liver disease

Semaglutide improves fatty liver disease and inflammation in people with HIV

Cardiovascular disease

Women with HIV need tailored advice on statins and heart disease risk

Ethnic & cultural minorities

Progress in reducing new HIV diagnoses much slower for Black men in the US

Resistance

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?

Injectable & long-acting PrEP

Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment

Pregnancy and vertical transmission

HIV medication dolutegravir not linked with increased blood pressure during pregnancy

Menopause

Switch to an integrase inhibitor leads to greater weight during and after the menopause

HIV prevention policy

Huge increase in PrEP uptake when services offer choice, flexibility and injectable PrEP, African study shows

PrEP science

Far fewer HIV infections in Australian PrEP users – consistent use is key

The search for a cure

Some children who start antiretrovirals very early may control HIV after stopping treatment

Cancer

Prostate cancer diagnosed later in US men with HIV

Cardiovascular disease

People-centred blood pressure management improves blood pressure in people with HIV

PrEP

Six-country African PrEP study achieves high levels of persistence and good adherence in young women

New & experimental HIV treatments

Broadly neutralising antibodies may be partners for long-acting antiretrovirals

PrEP

HIV diagnoses continue to fall in US states with high PrEP coverage, while others are left behind

New & experimental HIV treatments

Once-weekly antiretrovirals on the horizon

New & experimental HIV treatments

If one antibody won’t work, how about three? Or three in one?

The search for a cure

Varying dolutegravir distribution across the body may affect the drug’s ability to suppress the HIV reservoir

PEP

People need pathways from PEP to PrEP – and back again

Sexually transmitted infections prevention

Full analysis of French STI study dashes hopes for a gonorrhoea vaccine

Injectable & long-acting HIV treatment

Injectable treatment just as effective as standard HIV combination in Africa

Interviews

CROI 2024: Weekly lenacapavir / islatravir for HIV treatment

6 March 2024

At CROI 2024, Dr Amy Colson from the Community Resource Initiative in Boston spoke to aidsmap's Roger Pebody about islatravir and lenacapavir as a once-weekly oral HIV treatment.

CROI 2024: Injectable HIV treatment in Africa

7 March 2024

At CROI 2024, Professor Nicholas Paton from the London School of Hygiene and Tropical Medicine spoke to aidsmap's Roger Pebody about injectable HIV treatment in Africa.

CROI 2024: HIV remission in children

11 March 2024

At CROI 2024, Professor Deborah Persaud from Johns Hopkins University spoke to aidsmap's Roger Pebody about her study on HIV remission in children.

CROI 2024: Dolutegravir resistance

12 March 2024

At CROI 2024, Dr George Bello from the Malawian International Training and Education Center for Health spoke to aidsmap's Roger Pebody about dolutegravir resistance in Malawi.

CROI 2024: DoxyPEP

13 March 2024

At CROI 2024, Dr Manik Kohli from University College London spoke to aidsmap's Krishen Samuel about doxyPEP implementation and concerns about resistance.

CROI 2024: Event-based PrEP

19 March 2024

At CROI 2024, Dr Jenell Stewart from the University of Minnesota spoke to aidsmap's Krishen Samuel about event-based PrEP for women.

CROI 2024: Injectable treatment for people with adherence challenges

20 March 2024

At CROI 2024, Dr Aadia Rana from the University of Alabama at Birmingham spoke to aidsmap's Roger Pebody about injectable treatment for people with adherence challenges.

Conference bulletins

English

CROI 2024: STIs in San Francisco have fallen since doxyPEP roll-out, Tuesday 5 March 2024

(HTML)

CROI 2024: Once-weekly antiretrovirals on the horizon, Wednesday 6 March 2024

(HTML)

CROI 2024: Some children who start antiretrovirals very early may control HIV after stopping treatment, Thursday 7 March 2024

(HTML)

CROI 2024: HIV incidence much lower with consistent PrEP, Wednesday 13 March 2024

(HTML)

Spanish

CROI 2024: La tasa de ITS ha descendido en San Francisco desde la implementación de la doxyPEP. Martes, 5 de marzo de 2024

(HTML)

CROI 2024: Antirretrovirales de toma semanal en perspectiva, Miércoles 6 de marzo de 2024

(HTML)

CROI 2024: Algunos niños que empiezan a tomar los antirretrovirales muy pronto son capaces de controlar el VIH tras interrumpir el tratamiento. Jueves, 7 de marzo de 2024

(HTML)

CROI 2024: La incidencia del VIH es mucho menor cuando hay un uso constante de la PrEP, miércoles 13 de marzo de 2024

(HTML)

French

CROI 2024 : Les cas d’IST ont chuté à San Francisco depuis l’extension de la doxyPEP, Mardi 5 mars 2024

(HTML)

CROI 2024 : Des antirétroviraux à prise hebdomadaire à l'horizon. Mercredi 6 mars 2024.

(HTML)

CROI 2024 : Chez certains enfants, l'instauration très précoce d’un traitement antirétroviral peut leur permettre de contrôler le VIH après l'arrêt du traitement, jeudi 7 Mars 2024

(HTML)

CROI 2024 : L'incidence du VIH est beaucoup plus faible avec une PrEP continue, mercredi 13 mars 2024

(HTML)

Portuguese

CROI 2024: As IST em São Francisco diminuíram desde o lançamento do doxyPEP, terça-feira, 5 de março de 2024

(HTML)

CROI 2024: Antirretrovirais de toma única semanal no horizonte, 6 de março de 2024

(HTML)

CROI 2024: Algumas crianças que iniciam os antirretrovirais muito cedo podem controlar o VIH depois de interromperem o tratamento, quinta-feira, 7 de março de 2024

(HTML)

CROI 2024: Incidência do VIH muito mais baixa com PrEP consistente, Quarta-feira, 13 de março de 2024

(HTML)

Italian

CROI 2024: San Francisco, IST in calo dopo l'introduzione della doxyPEP, martedì 5 marzo 2024

(HTML)

CROI 2024: Nuovi antiretrovirali a monosomministrazione settimanale all'orizzonte, mercoledì 6 marzo 2024

(HTML)

CROI 2024: La somministrazione precoce di antiretrovirali nei neonati potrebbe in alcuni casi mantenere soppresso l'HIV dopo l'interruzione del trattamento, giovedì 7 marzo 2024

(HTML)

CROI 2024: Incidenza HIV in forte calo per chi assume la PrEP con costanza, mercoledì 13 marzo 2024

(HTML)

Russian

КРОИ 2024: Заболеваемость ИППП в Сан-Франциско снизилась после развертывания программы доксициклиновой постконтактной профилактики «доксиПостКП». Вторник, 5 марта 2024 г.

(HTML)

КРОИ 2024: На горизонте - антиретровирусные препараты, которые можно будет принимать раз в неделю Среда, 6 марта 2024 года

(HTML)

КРОИ 2024: Некоторые ВИЧ-инфицированные дети, которым ВААРТ начиналась проводиться очень рано, удерживают адекватный вирусологический контроль даже после прекращения терапии, Четверг, 7 марта 2024 года

(HTML)

КРОИ 2024: Заболеваемость ВИЧ-инфекцией гораздо ниже при продолжительном приеме ДоКП, Среда, 13 марта 2024

(HTML)